# Study of Neoadjuvant Endocrine Therapy in HR Positive and HER2 Negative Premenopausal Breast Cancer Patients

> **NCT06009627** · PHASE2,PHASE3 · COMPLETED · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 119 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** dalpiciclib、Exemestane、Gosserine
- **DRUG:** Docetaxel for injection、Epirubicin hydrochloride for injection、Cyclophosphamide for injection

## Key facts

- **NCT ID:** NCT06009627
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-04-11
- **Primary completion:** 2025-03-11
- **Final completion:** 2025-09-11
- **Target enrollment:** 119 (ACTUAL)
- **Last updated:** 2026-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06009627

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06009627, "Study of Neoadjuvant Endocrine Therapy in HR Positive and HER2 Negative Premenopausal Breast Cancer Patients". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06009627. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*